Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?
Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?
复制标题
DOI：
10.1210/jendso/bvaa205
复制
发表时间：
2021-03-01
影响因子：
4.1
通讯作者：
Melmed S
中科院分区：
文献类型：
--
作者：
Ho K;Fleseriu M;Kaiser U;Salvatori R;Brue T;Lopes MB;Kunz P;Molitch M;Camper SA;Gadelha M;Syro LV;Laws E;Reincke M;Nishioka H;Grossman A;Barkan A;Casanueva F;Wass J;Mamelak A;Katznelson L;van der Lely AJ;Radovick S;Bidlingmaier M;Boguszewski M;Bollerslev J;Hoffman AR;Oyesiku N;Raverot G;Ben-Shlomo A;Fowkes R;Shimon I;Fukuoka H;Pereira AM;Greenman Y;Heaney AP;Gurnell M;Johannsson G;Osamura RY;Buchfelder M;Zatelli MC;Korbonits M;Chanson P;Biermasz N;Clemmons DR;Karavitaki N;Bronstein MD;Trainer P;Melmed S
WHO内分泌肿瘤分类将垂体肿瘤指定为腺瘤。垂体神经内分泌肿瘤（PitNET）的命名变化引起了一些利益相关者的关注。该协会协调了Pneumonia Neoplasm Nomenclature（PANOMEN）研讨会，以解决这一问题。垂体发育生物学、病理学、神经外科、内分泌学和肿瘤学专家，包括内分泌学会、欧洲内分泌学会、欧洲神经内分泌学会、生长激素研究学会和国际垂体外科医师学会提名的代表。垂体腺瘤的临床流行病学、疾病表型、治疗和预后与大多数NET不同。绝大多数垂体腺瘤是良性的，不会对预期寿命产生不利影响。PitNET的命名变化并不能解决预后预测的主要挑战，将不确定的恶性肿瘤命名为良性垂体腺瘤，并可能对患者产生不利影响。由于流行病的限制，讲习班以虚拟方式进行，向所有与会者提供了关于每个专题的视听讲座和书面摘要。内容主席对反馈进行了整理和总结，并在由会议主席主持的虚拟写作会议上进行了讨论，会议产生了一份基于证据的文件草案，发送给所有参与者供审查和批准。目前还没有采用PitNET命名法的理由。PANOMEN研讨会建议保留腺瘤一词，并随着垂体肿瘤生物学的新证据出现而重新讨论该主题。
The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges.
登录
查看更多内容
影响因子：
28.4
作者：
Dasari, Arvind;Shen, Chan;Yao, James C.
通讯作者：
Yao, James C.
影响因子：
3.9
作者：
Asa, S. L.;Casar-Borota, O.;Trouillas, J.
通讯作者：
Trouillas, J.
影响因子：
5.8
作者：
Buurman, Hilke;Saeger, Wolfgang
通讯作者：
Saeger, Wolfgang
影响因子：
1.7
作者：
Chadha, NK;Repanos, C
通讯作者：
Repanos, C
影响因子：
39.2
作者：
HALL, WA;LUCIANO, MG;OLDFIELD, EH
通讯作者：
OLDFIELD, EH